Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Acorda Therapeutics Inc ACORQ

Healthcare Biotechnology
Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The Company markets Inbrija (levodopa inhalation powder), which is approved in the United States for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson’s disease treated with carbidopa... see more

Recent & Breaking News (OTCPK:ACORQ)

Acorda Announces Patent Trials and Appeal Board (PTAB) Institutes IPRs of AMPYRA Patents

Business Wire March 11, 2016

Acorda Has Filed Tender Offer Document Relating to Public Tender Offer For Biotie Therapies with Finnish Financial Supervisory Authority

Business Wire March 3, 2016

Acorda Therapeutics to Present at Two Investor Conferences in March

Business Wire March 1, 2016

Acorda Announces Expiration of the Hart-Scott-Rodino Waiting Period for Its Tender Offer for Biotie Therapies

Press Releases February 17, 2016

TomTom Telematics named Frost & Sullivan 2016 European Fleet Telematics Company of the Year

Press Releases February 17, 2016

Eutelsat Communications First Half 2015-2016 Results

Press Releases February 17, 2016

EUTELSAT COMMUNICATIONS : RÉSULTATS DU PREMIER SEMESTRE 2015-2016

Press Releases February 17, 2016

Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2015

Business Wire February 11, 2016

Acorda Therapeutics to Present at Two Investor Conferences in February

Business Wire February 4, 2016

Acorda to Host Conference Call to Discuss Fourth Quarter and Year End 2015 Results on February 11, 2016

Business Wire January 28, 2016

Acorda to Acquire Biotie Therapies

Business Wire January 19, 2016

Acorda Announces 2015 AMPYRA Sales, 2016 Financial Guidance and 2016/2017 Clinical Milestones at J.P. Morgan Healthcare Conference

Business Wire January 11, 2016

Acorda to Present at the 34th Annual J.P. Morgan Healthcare Conference

Business Wire December 22, 2015

Acorda Announces Departure of Chief Medical Officer (CMO); Company Appoints Burkhard Blank, M.D. as Interim CMO

Business Wire December 21, 2015

Acorda Presents Analyses on Use of Healthcare Services for Seizure Clusters at American Epilepsy Society Annual Meeting

Business Wire December 8, 2015

Acorda Initiates Phase 1 Clinical Trial of CVT-427, Inhaled Therapy for Acute Treatment of Migraines

Business Wire December 3, 2015

Acorda Therapeutics to Present at the Oppenheimer Annual Healthcare Conference

Business Wire November 30, 2015

Acorda Therapeutics to Present at Two Investor Conferences in November

Business Wire November 10, 2015

Acorda Provides Financial and Pipeline Update for 2015 Third Quarter

Business Wire October 22, 2015

Acorda Therapeutics to Host Conference Call to Discuss Third Quarter Results on October 22, 2015

Business Wire October 8, 2015